Analysts Set Intellia Therapeutics, Inc. (NASDAQ:NTLA) PT at $17.00

Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) have been assigned a consensus rating of “Hold” from the twenty-two analysts that are presently covering the stock, MarketBeat Ratings reports. Three research analysts have rated the stock with a sell recommendation, ten have issued a hold recommendation and nine have given a buy recommendation to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $17.00.

A number of research analysts have recently issued reports on NTLA shares. Guggenheim lowered shares of Intellia Therapeutics from a “buy” rating to a “neutral” rating in a research note on Monday, October 27th. HC Wainwright lowered their price objective on Intellia Therapeutics from $18.00 to $15.00 and set a “buy” rating on the stock in a report on Monday, November 10th. Bank of America cut their target price on Intellia Therapeutics from $36.00 to $30.00 and set a “buy” rating for the company in a research note on Monday, October 27th. Citigroup restated a “market outperform” rating on shares of Intellia Therapeutics in a research note on Tuesday, October 28th. Finally, Wall Street Zen lowered Intellia Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday.

Intellia Therapeutics Price Performance

NASDAQ NTLA opened at $12.50 on Thursday. The firm’s fifty day moving average price is $9.41 and its 200 day moving average price is $12.78. Intellia Therapeutics has a 12 month low of $5.90 and a 12 month high of $28.25. The company has a market capitalization of $1.45 billion, a price-to-earnings ratio of -2.93 and a beta of 2.05.

Intellia Therapeutics (NASDAQ:NTLA) last released its quarterly earnings results on Thursday, November 6th. The company reported ($0.92) EPS for the quarter, topping the consensus estimate of ($1.02) by $0.10. The company had revenue of $13.78 million for the quarter, compared to analyst estimates of $14.12 million. Intellia Therapeutics had a negative return on equity of 57.01% and a negative net margin of 774.94%.The firm’s revenue was up 51.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($1.34) earnings per share. As a group, sell-side analysts forecast that Intellia Therapeutics will post -5.07 earnings per share for the current year.

Insider Buying and Selling

In related news, EVP Birgit C. Schultes sold 8,508 shares of the firm’s stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $9.21, for a total transaction of $78,358.68. Following the sale, the executive vice president owned 98,533 shares in the company, valued at approximately $907,488.93. This trade represents a 7.95% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP James Basta sold 10,397 shares of the company’s stock in a transaction on Monday, January 5th. The shares were sold at an average price of $9.21, for a total value of $95,756.37. Following the completion of the transaction, the executive vice president owned 101,528 shares of the company’s stock, valued at $935,072.88. The trade was a 9.29% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 53,051 shares of company stock worth $488,600 in the last three months. Corporate insiders own 3.10% of the company’s stock.

Institutional Trading of Intellia Therapeutics

A number of institutional investors have recently modified their holdings of NTLA. Caitong International Asset Management Co. Ltd acquired a new stake in Intellia Therapeutics in the third quarter valued at approximately $30,000. Blue Bell Private Wealth Management LLC purchased a new position in shares of Intellia Therapeutics in the third quarter valued at $30,000. Advisory Services Network LLC acquired a new stake in Intellia Therapeutics during the 3rd quarter valued at $33,000. Headlands Technologies LLC purchased a new stake in Intellia Therapeutics during the 2nd quarter worth $26,000. Finally, Danske Bank A S purchased a new stake in Intellia Therapeutics during the 3rd quarter worth $50,000. Hedge funds and other institutional investors own 88.77% of the company’s stock.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.